Biotech News
Annovis Bio Granted U.S. Patent Covering New Crystalline Form of Buntanetap
Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 12,780,831, titled “ Solid Forms of Posiphen D-Tartrate .”
